First Time Loading...

Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Watchlist Manager
Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Watchlist
Price: 30.21 USD -2.01%
Updated: May 6, 2024
SUPN
/
Income Statement
/
Revenue

Supernus Pharmaceuticals Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Supernus Pharmaceuticals Inc
Revenue Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Revenue
$607.5m
CAGR 3-Years
5%
CAGR 5-Years
8%
CAGR 10-Years
48%
Johnson & Johnson
NYSE:JNJ
Revenue
$85.6B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$45.5B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$55.1B
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Revenue
$61.4B
CAGR 3-Years
14%
CAGR 5-Years
7%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Revenue
$35.9B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
5%

Supernus Pharmaceuticals Inc
Revenue Breakdown

Breakdown by Geography
Supernus Pharmaceuticals Inc

Not Available

Breakdown by Segments
Supernus Pharmaceuticals Inc

Total Revenue: 607.5m USD
100%
Product: 573.9m USD
94.5%
Qelbree: 140.2m USD
23.1%
Gocovri: 119.6m USD
19.7%
Oxtellar X R: 113.4m USD
18.7%
Trokendi Xr: 94.3m USD
15.5%
Apokyn: 75.1m USD
12.4%
Royalty: 33.6m USD
5.5%
Manufactured Product, Other: 31.3m USD
5.1%
Show More
Show Less

See Also

What is Supernus Pharmaceuticals Inc's Revenue?
Revenue
607.5m USD

Based on the financial report for Dec 31, 2023, Supernus Pharmaceuticals Inc's Revenue amounts to 607.5m USD.

What is Supernus Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
48%

Over the last year, the Revenue growth was -9%. The average annual Revenue growth rates for Supernus Pharmaceuticals Inc have been 5% over the past three years , 8% over the past five years , and 48% over the past ten years .

ALPHA SPREAD
Join more than 134,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.